CYPB - Cypress BioScience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John S. Baker who wrote (469)	12/16/1998 7:59:00 AM
From: muddphudd	Read Replies (1) of 586

It has been dead here for a while. I guess we are all waiting to hear official word from the FDA and notice of a marketing partner from CYPB. Saw this on Immunex (pseudo-media competitor of CYPB): Immunex Corp. Reiterated 'Buy' at Salomon Smith Barney Bloomberg News December 14, 1998, 11:37 a.m. ET Princeton, New Jersey, Dec. 14 (Bloomberg Data) -- Immunex Corp. (IMNX US) was reiterated ''buy'' by analyst Meirav Chovav at Salomon Smith Barney. The 12-month target price is $120.00 per share. In order for CYPB to "make it" it will need this type of coverage.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next